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ABST RACT
Over the past years, bone and adipose tissue have gained interest from
researchers in the light of their secretory profiles, being able to produce
active molecules, with the final effect of regulating energy homeostasis.
Both adipocytes and osteoblasts originate in the pluripotent
mesenchymal stem cell and this common origin has been proposed as
the core of the fat-bone relationship. The central nervous system might
be the third player in this association, capable of integrating signals.
Numerous adipose tissue secreted factors that influence energy
homeostasis and bone have been described: leptin, adiponectin, lipocalin
2, and inflammatory cytokines (e.g. IL-1, IL-6 and TNF-α). Similarly,
osteocalcin, the most abundant bone protein, has been shown to elicit
numerous central and peripheral endocrine functions. In this paper, we
provide a review of the current literature regarding the bone-adipose
tissue-central nervous system axis and a brief description of the several
underlying molecular mechanisms.

Introduction
For many years, both bone and adipose tissue have been
only considered as storage and support sites. However, in
the more recent past, their secretory profiles have gained
increasing attention, as it has been shown that both tissues
produce molecules with autocrine, paracrine, and
endocrine effects, with the final result of regulating energy
homeostasis [1, 2]. The interaction between the skeleton
and the adipose tissue had initially been studied with focus
on mechanical loading and strain, but, as research has
gained more insight into the physiology and pathology of
both systems, molecular interconnections have started to
become apparent.
Both adipocytes and osteoblasts originate from the
same precursor – the pluripotent mesenchymal stem cell
(MSC) – and this common origin has been proposed as
being at the core of the fat-bone relationship [3]. The
central nervous system might be a third player in this
relationship, capable of integrating signals. MSCs are
regulated by endocrine, paracrine, and autocrine signals,
and their preferential differentiation towards either
adipocytes or osteoblasts might lead to imbalances and
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contribute to bone loss. However, the interactions are far
from being straightforward. Many of the studied molecules
have been found to have dual, opposing effects and/or
effects that differ in vivo vs. in vitro.
The adipose tissue secretes more than 50 hormones and
signaling molecules, called adipokines, which are known
to influence the physiological processes involved in
glucose metabolism, immunity, and energy [4].
Adipokines have the ability to respond to signals from the
central nervous system (CNS) and enable crosscommunication between various organs [5], allowing fat
tissue to be involved in the complex control of bone
biology.
Similarly, in recent years, bone has emerged as an
endocrine organ that secretes hormones and regulates
energy metabolism, with osteocalcin (the most abundant
bone protein) being shown to exert numerous endocrine
functions, both centrally and peripherally [6]. Studies have
revealed an association between bone metabolism,
adipokines, inflammatory cytokines and brain, but these
interactions are not fully explained.
In this paper, we aim to provide a review of the current
literature regarding the bone-adipose tissue-central
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nervous system axis and a brief description of some
underlying molecular mechanisms.
Our review is based on a comprehensive search of the
current literature in order to identify the relevant articles
published until August 2020 in the PubMed database. The
following terms were used in different combinations to
generate the search: “adipose tissue”, “bone”, “brain”,
“leptin”, “adiponectin”, “lipocalin 2”, “osteocalcin”,
“fibroblast growth factor 23”, “inflammatory cytokines”.
All identified articles were English language, full-text
papers. We selected recent original articles, but some
relevant reviews and older articles were also included.

Discussions
Mesenchymal stem cell – the same origin for adipocytes
and osteoblasts
Mesenchymal stem cells (MSCs), known as marrow
stromal cells, are multipotent stem cells which can be
found in most organs and tissues, such as fatty tissue, bone
marrow, liver, kidney, lung, muscle, umbilical cord, and
placenta [7]. Friedenstein et al. discovered mesenchymal
stem cells in 1970 and described them as a nonhematopoietic stem cell population in the bone marrow,
spindle-shaped and “adherent” [8]; in the following years,
the same research team described that non-hematopoietic
stem cells had stem-like characteristics and maintained the
potential to differentiate between bone, cartilage, and
fibrous tissue in vivo [9, 10]. Caplan was the first to use the
term “MSC” in 1991 to describe those cells that were able
to differentiate between osteoblasts, chondroblasts,
adipocytes, and myoblasts [11]. According to the
International Society for Cellular Therapy, one of the most
important criteria for a cell to be classified as mesenchymal
stem cell (MSC) is the ability to differentiate between an
osteoblast, chondroblast, or adipocyte in vitro [12]. Given
the fact that adipocytes and osteoblasts share the same
origin, the hypothesis that MSCs might play a role in the
fat-bone relationship became apparent [13]. An alteration
in MSC differentiation where adipocyte lineage formation
is favored over the osteoblast lineage might lead to an
imbalance in bone turnover and could contribute to bone
loss. In vitro experiments have demonstrated that when
adipogenesis is stimulated, osteoblast formation is
inhibited, and reversely, adipogenesis is inhibited when the
factors that favor osteoblastogenesis are dominant [14].
The brain’s effects on the bone
The CNS, especially the hypothalamus, has a major
role in the control of energy homeostasis. The arcuate
nucleus (ARC), the most important site in the
hypothalamus, is involved in a number of neuroendocrine
and physiological functions. ARC integrates the actions of
metabolic mediators such as leptin, insulin, and ghrelin.
Localized in the ARC, agouti-related protein (AgRP)
18

neurons co-expressing neuropeptide Y (NPY) with a role
in promoting food consumption and suppressing energy
expenditure, also play a role in bone metabolism [15,16].
The anorexigenic neurons that co-express cocaine and
amphetamine
related
transcript
(CART)
and
proopiomelanocortin (POMC) are also involved in energy
homeostasis. Cytokines and hormones are responsible for
the central control of bone mass. One of them, leptin, is a
modulator of NPY, can activate POMC neurons, and could
affect bone resorption via central effects on CART [17–
19].
Adipose tissue as an endocrine organ
The endocrine function of adipose tissue plays an
important role in the crosstalk between organs and tissues.
Adipokines present both pro-inflammatory and antiinflammatory properties. Signals from adipocytes that
influence brain control of the bone mass have been
identified, revealing the complex relationship between
energy metabolism, its regulation, and bone homeostasis.
Estrogens and vitamin D have both been studied
extensively in the context of fat-bone crosstalk. Higher
estrogen levels in obese individuals, owing to adipose
aromatase expression, provide one simple molecular
explanation for the positive relationship between excessive
fat and bone metabolism; on the other hand, decreased
vitamin
D
bioavailability
(and
secondary
hyperparathyroidism), common in obese individuals, are
consistent with the negative side of the relationship [20–
22].
We now further discuss a number of factors secreted
by adipocytes known to affect bone remodeling such as:
leptin,
adiponectin,
pro-inflammatory
cytokines
(interleukins 1 and 6 (IL-1, IL-6) and tumor necrosis
factor-alpha (TNF-α)).
a. Leptin
Leptin, derived from the Greek word “leptos” (meaning
thin) and the product of the ob gene, is a small polypeptide
hormone produced predominantly by the adipocyte (white
adipose tissue [WAT]), which regulates weight, body
metabolism, appetite, and reproductive function via the
LEP receptor [23]. The mutation of the ob gene can cause
obesity in mice; leptin deficiency in ob/ob mouse mutants
leads to morbid obesity, hypothermia, hyperphagia and
neuroendocrine abnormalities [24]. In addition, leptin
receptor mutations causing leptin insensitivity lead to
hyperphagia, morbid obesity, hypercorticism and other
neuroendocrine abnormalities in mice (db/db mice) [25].
Leptin’s main site of action is the brain (at the
hypothalamic level); intravenous leptin injections activate
neurons in the arcuate (ARC), ventromedial, and
dorsomedial hypothalamic nuclei [26]. The ARC is
located in the third ventricle ventrally and contains neurons
that produce cocaine and amphetamine modulates
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transcript (CART), POMC, AgRP, neuropeptide Y (NPY),
and gamma-aminobutyric acid (GABA), all of which are
involved in energy balance regulation. POMC/CARTsecreting neurons are involved in catabolic pathways,
while NPY/AgRP/GABA producing neurons have
anabolic effects [27].
Leptin inhibits the action of NPY and AgRP in the
arcuate nucleus of hypothalamus, and increases the action
of POMC and CART in order to decrease food intake
[28,29].
Leptin impacts bone metabolism through direct and
indirect mechanisms, via peripheral and central pathways.
In vitro data suggest a direct impact of leptin on bone cells,
with a high level of leptin increasing osteoblast
differentiation. In their study, Cornish et al. indicate a
modest direct effect of leptin on bone cells resulting in a
slight reduction of bone fragility. Leptin promotes growth
in cultures of osteoblasts and chondrocytes [30]. Steppan
et al. show an increase in bone size and bone mass after the
in vivo administration of leptin to ob/ob mice [31]. These
studies suggest that leptin has direct anabolic effects on
osteoblasts. There is also evidence that leptin increases the
osteoprotegerin levels and decreases the RANK-ligand
levels in human marrow stromal cells; as well, it inhibits
osteoclastogenesis in mouse bone marrow cultures [32].
These findings indicate a positive correlation between fat
and bone.
Tsuji et al. demonstrated a direct effect of leptin on
bone growth through the fibroblast growth factor 23 (FGF23) [33]. Similar to adipocytes in peripheral body fat,
adipocytes in the bone marrow also secrete leptin and these
local effects contribute to leptin-bone complexity [34].
Conversely, the intra-cerebroventricular infusion of
leptin in ob/ob and wild-type mice reduces bone mass,
indicating that, when acting via central mechanisms, leptin
decreases bone mass [18]. Leptin’s involvement in
osteoporosis pathophysiology has been hypothesized, as
some authors have found that it correlates positively with
bone mineral density (BMD) and bone mineral content
(BMC) as indirect clinical indicators of osteoporosis
[23,35,36]; however, there have also been studies that
found a lack of correlation between leptin, BMD, and bone
turnover markers [37,38].
b. Adiponectin
Adiponectin, a protein hormone produced by
adipocytes, was first described in 1995 by Scherer and
coworkers. It consists of 244 amino acids, with an Nterminal signaling sequence, a hypervariable region, a
collagenous domain, and a carboxy-terminal globular
domain C1q like [39]. There are two main receptors for
adiponectin, AdipoR1 and AdipoR2, which belong to a
domain similar to G protein-coupled receptors (GCPR).
Another receptor, T-cadherin, binds adiponectin in C2C12
myoblasts and muscle, and it is important for adiponectinmediated cardioprotection in mice [40,41]. AdipoR1

expression is ubiquitous, but the major expressing tissue is
skeletal muscle, while AdipoR2 is predominantly
expressed in the liver [42]. These receptors are also
expressed in the brain. AdipoR1 and AdipoR2 are involved
in glucose and lipid metabolism, mediating increased
AMP-activated kinase (AMPK) and PPARs activities [43].
Due to the wide distribution of different receptors in the
brain, adiponectin has a variety of central effects, such as
thermogenesis regulation, energy expenditure, food intake,
locomotor activity, cognition, anxiety, and mood [44].
Also, it is one of the adipokines with anti-inflammatory,
antiatherogenic, antidiabetic, and cardioprotective effects
[45]. Adiponectin is found in high concentrations in the
blood, more specifically within a range of 5-30 ug/mL [46].
The adiponectin level is decreased in obese people
compared to lean people [47]. Qi et al. have found that the
concentration of adiponectin in the cerebrospinal fluid was
1-4% of that in the serum and demonstrated that the intracerebroventricular injection of adiponectin reduced body
weight in normal and Lepob/ob mice without affecting
food intake [48]. Cisternas et al., using cultured primary rat
hippocampal neurons and mouse hippocampus slices,
demonstrated a direct role of adiponectin and resistin in
glucose metabolism in the hippocampus, through the
increase of glucose uptake, ATIP production and
glycolysis [49].
Adiponectin might be a mediator of fat-bone
relationship. Due to its anti-inflammatory effects,
adiponectin suppresses TNF-α-induced nuclear factor kB
(NF-kB) activation [50]. Receptors for adiponectin,
AdipoR1 and AdipoR2, have been found on both osteoclast
and osteoblast; most in vitro research suggests that
adiponectin stimulates the proliferation and differentiation
of the osteoblast, while inhibiting osteoclastogenesis
[51,52]. These effects can be attributed to the involvement
of adiponectin in RANK/RANKL/OPG axis. RANKL is a
member of the tumor necrosis factor (TNF) family and
influences the osteoclast activation responsible for bone
resorption by binding to RANK. OPG (osteoprotegerin)
secreted by osteoblasts and osteogenic stromal cells acts as
a decoy receptor for RANKL and reduces the osteoclast
differentiation, thereby inhibiting bone resorption [53].
Shinoda et al. analyzed the adiponectin effects on bone
metabolism in adiponectin deficient and overexpressing
transgenic mice; their study proposed opposing effects of
adiponectin on bone formation, with circulating
adiponectin directly inhibiting osteogenesis, but also
having positive effects via the enhancement of insulin
signaling and with locally produced adiponectin exerting
positive effects via autocrine/paracrine pathways [54].
Clinical study results are contradictory when it comes
to the association between adiponectin and BMD. Some
studies show a negative correlation between adiponectin
levels and bone mineral density (BMD) [55–57].
Regarding fractures, Barborur et al. reported that men with
a high adiponectin level, had a higher risk of fracture,
19
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independent of age, diabetes, body composition, and hip
BMD [58], whereas other studies found no association
between the risk of fracture and adiponectin level [59].
Further research is needed for a better understanding of the
physiological role of adiponectin in bone biology and
central function.
c. Lipocalin 2
Lipocalin-2 (LCN 2), known as neutrophil gelatinaseassociated lipocalin (NGAL) or 24p3, is a member of the
lipocalin superfamily and is involved in the inflammatory
process [60]. LCN2 is expressed especially in WAT [61],
but other sources such as the kidney, liver, spleen, immune
cells, bone marrow and chondrocytes have been identified.
This adipokine is involved in a series of physiological and
pathophysiological processes such as metabolic
homeostasis, inflammation, the apoptosis of hematopoietic
cells, the transportation of fatty acids, and metabolic
disorders [62]. Circulating LCL2 concentrations were
positively associated with adiposity, hyperglycemia,
insulin resistance, and CRP levels [63]. The general view
has been that LCN2 levels are mainly associated with
excessive adiposity [61], but recent studies have
challenged this view, revealing that LCN2 is expressed by
osteoblasts at much higher levels (tenfold higher) than in
WAT or other organs. Osteoblast-derived LCN2 crosses
the blood-brain barrier and suppresses appetite after
binding to the MC4R in paraventricular and ventromedial
neurons of the hypothalamus with potency-like leptin. This
osteoblast-derived ligand for MC4R represents one of the
means through which bone coordinates energy balance, via
central feedback [64]. The pathways in which LCN2 is
involved are, at this moment, not completely understood.
d. Inflammatory Cytokines
Obesity is associated with a higher concentration of
pro-inflammatory and anti-inflammatory cytokines, such
as: IL-10, IL-6, IL-8, IL-1 receptor antagonist (IL-1Ra) and
TNF-α. A various number of cytokines is known to
influence bone cell functioning.
Interleukin 1 (IL-1)
Il-1 family has been associated with inflammation more
than any other cytokine family. Ten members of the IL-1
family have been identified: IL-1α, IL-1β, IL-1Ra, IL-18,
IL-33, IL-36Ra, IL-36α, IL-36β, IL-36γ, IL-37, IL-38 [65].
The peripheral immune system, bone cells, glia, and neural
cells in the central nervous system (CNS) are the
expression sites of IL-1 [66]. In vitro and in vivo studies
showed that IL-1 is a stimulator for bone resorption, with
effects on osteoclasts – both direct and indirect, by
stimulating
RANK
production.
IL-18
inhibits
osteoclastogenesis and it has variable effects on osteoblasts
[67–71].
Interleukin 6 (IL-6)
IL-6 is a cytokine that plays different and opposing
roles in cells and tissues. A high percentage of circulating
IL-6 is derived from adipose tissue, but chondrocytes,
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osteoblasts, and skeletal and smooth muscle cells also
produce it in variable amounts [72,73]. In his study,
Wueest demonstrated that IL-6 induces the release of free
fatty acid and leptin from adipocytes, therefore affecting
glucose metabolism [73]. This interleukin also has a
number of effects in the bone, influencing both osteoblast
and osteoclast differentiation and activities [74]. IL-6 acts
directly on osteoclast progenitors, suppressing their
differentiation by inhibiting RANKL signaling pathways,
with the final effect of decreasing bone resorption [75].
Yang et al. reported that IL-6 KO mice presented low bone
mass and decreased osteoblast number; IL-6 appeared to
play a role in the early stages of fracture healing (delayed
in IL-6 KO mice) [76]. Because IL-6 acts on both
peripheral and central nervous system, the mechanism is
still not fully understood.
Tumor necrosis factor alpha (TNF-α)
TNF-α and TNF-β are two similar peptide members of
the TNF superfamily. Adipocytes produce TNF-α, but
macrophages in the stromal vascular fraction are the main
source. TNF-α is also produced by monocytes, endothelial
cells, astrocytes, lymphocytes, neutrophils, and smooth
muscle cells. It is a pro-inflammatory cytokine and a potent
lipid metabolism and insulin signaling receptor. TNF-α
also exerts multiple actions on bone cells, such as inducing
bone resorption (both in vitro and in vivo) by stimulating
the proliferation and differentiation of osteoclasts
precursors or activating mature osteoclasts; a direct
inhibitory effect on osteoblasts has also been reported
[77,78].
Another interesting manner through which TNF-α and
IL-1β impact bone health is through upregulation of
osteoblast expression of 11β-HSD1, enhancing the
negative effects of cortisol [79].
Other interleukins
The effects of other interleukins have also been
described. For example, interleukin 4 inhibits osteoclast
and osteoblast activity, interleukin 11 stimulates
osteoclastogenesis
and
osteoblast
differentiation,
interleukin 8 stimulates bone resorption, interleukin 10
inhibits osteoclastogenesis and osteoblastogenesis,
interleukin 12 inhibits osteoclastogenesis, interleukin 13
inhibits osteoclast and osteoblast activity, interleukin 15
stimulates osteoclastogenesis, and interleukin 7, 17 have
variable effects [69].
Bone as an endocrine organ
a. Osteocalcin
Osteocalcin (OC), also known as bone γ-carboxy
glutamic acid protein, is the most abundant noncollagenenous protein in bone and vitamin K-dependent
protein. OC is an endocrine hormone and it regulates
multiple organs, such as the brain, the pancreas, and the
gonads. A low-level of OC has been reported in the
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vascular smooth muscle cell, the brain, the kidney, the
intestine, the bone marrow megakaryocytes, and the
endothelial progenitor cells [80-82]. OC is produced by
osteoblasts and it is a marker of bone formation, mostly
involved in the process of mineralization. Its secretion
by osteoblasts is controlled by the osteotesticular
protein tyrosine phosphatase (OST-PTP) encoded by
Esp (embryonic stem cell phosphatase) gene expressed
in osteoblasts [81]. OC exists in two forms:
undercarboxylated (uOC) and carboxylated (cOC). Espdeficient mice produce more undercarboxylated
osteocalcin resulting in more insulin secretion, better
insulin
sensitivity,
and
hypoglycemia,
while
overexpression of Esp produces the opposite results. In
their study, Lee et al. showed that uOC regulates glucose
metabolism in mice [82] by increasing the expression of
adiponectin by adipocytes. OC also increases B-cell
proliferation and insulin production [83]. Ferron et al.
(2012) tested the therapeutic potential of the intermittent
administration of osteocalcin; daily injections with uOC
were found to improve insulin resistance and glucose
tolerance in obese mice on a high-fat diet [84]. A
relationship between glucose, fat metabolism, and
osteocalcin has also been described in humans [85].
Serum osteocalcin has been widely used to evaluate
bone metabolism as a bone formation marker, but new
evidence suggests that it might also represent an
endocrine link between bone and energy metabolism,
with central roles. The uncarboxylated form of OC can
pass through the blood-brain barrier, accumulate in the
brainstem, thalamus, and hypothalamus, and bind to
neurons [86]. One study indicated that osteocalcin might
function as a neuropeptide in the brain [87], while other
studies revealed a central effect of OC through the
stimulation of the neurotransmitter production [83]. A
new study on mice and humans by Karsenty et al. (2019)
has revealed that immediately after the brain recognizes
a threatening situation, circulating osteocalcin levels
quadruple very quickly (within 2 minutes in mice). In
the
absence
of
normal
adrenal
function,
adrenalectomized rodents and adrenal-insufficient
patients can develop a normal stress response; these
findings showed that circulating levels of osteocalcin
are enough to induce the acute stress response [88].
Based on these results, we can classify bone as a stress
organ, and osteocalcin as a stress hormone. Further
studies are necessary to unravel the link between brain
and the glutamatergic neurons in bone and establish
other inter-organ relationships.
b. Fibroblast growth factor-23 (FGF23)
FGF23, a member of the FGF family, is a glycoprotein
produced predominantly in bone by osteoblasts and
osteocytes with low levels in other tissues such as the
ventrolateral thalamic nucleus of the brain [89]. FGF23

regulates mineral metabolism by inhibiting urinary
phosphate reabsorption and suppression of 1,25(OH)2D3
production in the kidney. Klotho, localized in the proximal
and distal tubules in the kidney, testis, sinoatrial node, and
possibly bone, is a co-receptor for FGF23 [90–92]. The
absence of Klotho or FGF23 leads to increased serum
levels of 1,25 (OH)2D3, therefore Klotho-deficient mice
and FGF23-deficient mice have been reported with
hypercalcemia and hyperphosphatemia [93]. Murali et al.
found that FGF23 controls osteopontin secretion indirectly
by suppressing alkaline phosphatase transcription and
phosphate production in osteoblastic cells in a Klothoindependent manner [92].
High levels of plasma FGF23 have been found in
patients with chronic kidney disease, cardiovascular
diseases, and inflammatory and metabolic diseases [94].
Inflammation proved to be a significant trigger of FGF23
formation, and inflammatory cytokines are direct
regulators of FGF23 in osteoblast; TNF-α plays a
predominant role in FGF23 production [95,96]; Glosse et
al. demonstrated that a high fat diet stimulates FGF23
production through TNF-α formation in rodents [97].
Leptin
administration
increases
serum
FGF23
concentration and decreases serum 1,25(OH)2D3
concentration in leptin-deficient ob/ob mice to values
observed in lean control mice [33].
There is no clear evidence that FGF23 is produced by
adipose tissue, but adipocytes express other members of
the FGF family (FGF19, FGF21) that could be involved in
energy regulation [98,99]. A number of clinical studies
have described an independent association between higher
FGF23 levels and adiposity (expressed through BMI and
abdominal adipose tissue) in non-CKD population,
suggesting that FGF23-related mechanisms might provide
additional explanation for the skeletal changes seen in
obesity [100, 101].

Highlights
✓ Adipose tissue plays an important role in the crosstalk
between organs and tissues.
✓ Leptin impacts bone metabolism through direct and
indirect mechanisms, via peripheral and central
pathways.

Conclusions
Recent discoveries in the fields of molecular biology,
enzymology, and physiology confirm the existence of a
biocybernetic connection between fat and bone, modulated
by the central nervous system. Understanding the
interdependence between these systems is crucial in
developing new drugs, treatment guidelines, and reducing
the prevalence of metabolic and cardiovascular diseases in
general.
21
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Following the introduction of the term internal
homeostasis by Claude Bernard in the 19th century, it was
only a matter of time to subdivide and extrapolate this
notion to smaller systems as our understanding of their
functions and interactions to each other has increased.
Studies on metabolic homeostasis identified leptin as a
central modulator for the neuroendocrine axes and linked
its levels to bone turnover. The hormones produced by the
adipose tissues can stimulate adipogenesis and limit
osteoblastogenesis in vitro, but the intricacy of the
mechanisms seems to be insufficiently elucidated since
there are uneven results in vivo. In this regard, further
clarification of the inter- and intracellular signaling that
governs the molecular crosstalk between bone and fat is
needed. Furthermore, bone formation, resorption, and
utilization of energy substrates are under subcortical
control involving the hypothalamus, various cytokines, and
multi-synaptic pathways. The complex relationship
between these three different systems should be
reconsidered using a unitary approach on energy and
metabolic homeostasis in order to translate possible
therapeutic implications into useful and safe future drugs.
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